# Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

> **NCT01623115** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 486 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Placebo (for alirocumab)
- **DRUG:** Lipid Modifying Therapy (LMT)

## Key facts

- **NCT ID:** NCT01623115
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-04
- **Final completion:** 2014-12
- **Target enrollment:** 486 (ACTUAL)
- **Last updated:** 2016-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01623115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01623115, "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01623115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*